Drug Profile
BY 963
Alternative Names: BY-963; SonoRxLatest Information Update: 13 Feb 2003
Price :
$50
*
At a glance
- Originator ImaRx Therapeutics
- Developer ALTANA Group; Bracco
- Class Contrast media; Phosphatidylcholines
- Mechanism of Action Ultrasonography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Gastrointestinal disorders
Most Recent Events
- 30 Apr 2002 Discontinued - Phase-III for Gastrointestinal disorders (diagnosis) in Central Europe (PO)
- 30 Apr 2002 Discontinued - Phase-III for Gastrointestinal disorders (diagnosis) in Germany (PO)
- 16 Nov 1999 ImaRx Pharmaceutical has been acquired by DuPont